JPRN-jRCT2080222556未知3 期
A phase 3, multicenter, open-label study of naldemedine in patients with non-malignant chronic pain and opioid-induced constipation receiving S-8117 (Oxycodone hydrochloride hydrate)
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Patients with non-malignant pain who meet the following criteria:
- •Patients who initiated to receive S-8117 for treatment of non-malignant chronic pain and confirmed the occurrence of OIC
- •Patients whose SBM (spontaneous bowel movement) frequency per week is less than three times, and who experience at least one of the following symptoms of bowel movements
- •a) Straining during bowel movement
- •b) Feeling of incomplete evacuation
- •c) Passage of hard stools or pellets
排除标准
- •Patients with constipation potentially attributable to causes other than opioid analgesics
- •Patients with significant gastrointestinal disorders
- •Patients with previous or present allergy or hypersensitivity to opium alkaloids
- •Patients with hepatic or renal disorders, etc
研究者
相似试验
未知
3 期
A phase 3, multicenter, open-label study of naldemedine in patients with non-malignant pain and opioid-induced constipatioJPRN-jRCT2080222393SHIONOGI & CO., LTD.40
未知
3 期
A phase 3, multicenter, open-label study of naldemedine in cancer patients with opioid-induced constipation - extension studyCancer patients with opioid-induced constipation (OIC)JPRN-jRCT2080222293SHIONOGI & CO., LTD.100
进行中（未招募）
1 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AMedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850Hemophilia AEUCTR2020-002215-22-NLBioverativ Therapeutics Inc.90
进行中（未招募）
3 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AHemophilia AJPRN-jRCT2031210133Tanaka Tomoyuki262
进行中（未招募）
1 期
ong-term safety and efficacy of BIVV001 in Previously Treated Patients with hemophilia AHemophilia AEUCTR2020-002215-22-BEBioverativ Therapeutics Inc.267